HK inno.N said on Monday that its K-CAB (ingredient: tegoprazan), a treatment for gastroesophageal reflux disease (GERD), has been officially launched in Singapore.
HK inno.N held a symposium at Conrad Centennial Singapore to commemorate the launch of the drug inviting gastroenterologists in Singapore to share their latest insights on the leading P-CAB-based GERD treatment.
K-CAB is a P-CAB-based GERD treatment characterized by its rapid onset of action within 30 minutes of taking the drug, and its efficacy and safety for long-term use up to six months. It is Korea's 30th new drug and recorded overseas prescription sales of over 130 billion won (approximately $98 million) in 2022.
Professor Jung Hwoon-yong of Gastroenterology at Asan Medical Center shared how K-Cap was able to overcome the limitations of proton pump inhibitors (PPIs), and congratulated the Singaporean medical community on the launch of K-CAB, thus improving the GERD treatment options.
K-CAB was approved in Singapore in February and HK inno.N finished exporting the product to its local partner, UITC, who is responsible for managing the local sales and marketing.
K-CAB has entered 35 countries outside of Korea in the form of technology exports or finished product exports. Of these, the company has completed local launches in six countries including China, Mongolia, the Philippines, Mexico, Indonesia, and Singapore.
The company is also preparing to launch the drug in Peru, where it received a license in July.
In the U.S., where the company conducted a technology transfer, its local partner Sebela is conducting phase 3 clinical trials. The company is gradually expanding to other countries in Southeast Asia, and Central and South America by obtaining the necessary licensing.
"Singapore's pharmaceutical market has grown at a compound annual growth rate of 11 percent over the past three years,” said HK inno.N CEO Kwak Dal-won. "We will continue to work closely with our local partners to ensure the successful approval and launch of K-CAB overseas."